Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909242 | 1.00 | PARP1 (0.42) | PARP1ACHEELANETDP1NPC1 | |
| SCHEMBL26697710 | 0.81 | PARP1 (0.40) | PARP1ACHEELANETDP1NPC1 | |
| SCHEMBL21497074 | 0.81 | ACHE (0.44) | PARP1ACHEELANEHSP90AB1CYP1A2 | |
| SCHEMBL14842829 | 0.81 | PARP1 (0.47) | PARP1ACHEELANETDP1CYP1A2 | |
| SCHEMBL26679775 | 0.81 | CYP1A2 (0.43) | PARP1ACHEELANENPC1RAB9A | |
| SCHEMBL14842795 | 0.81 | PARP1 (0.47) | PARP1ACHEELANEHSP90AB1TNKS | |
| SCHEMBL3337344 | 0.79 | PARP1 (0.44) | PARP1ACHEELANETDP1PSMB8 | |
| SCHEMBL30013654 | 0.79 | PARP1 (0.44) | PARP1ACHEELANETDP1PSMB8 | |
| SCHEMBL3107616 | 0.78 | KMT2A (0.39) | PARP1ACHEELANETDP1NPC1 | |
| SCHEMBL10924247 | 0.77 | ACHE (0.38) | PARP1ACHEELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025096494-A1 | UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| CN-119060060-A | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-11-14 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| CN-110913855-B | Imidazole-containing ALK2 kinase inhibitors | 拜奥克里斯特制药公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-7713985-B2 | Adenosine Aa2 receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713985-B2 | Adenosine Aa2 receptor antagonists | SCHERING CORPORATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | disclosed |
| EP-2038285-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORP (US) | 2010-02-17 | — | — | EP | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2008-10-16 | — | — | US | disclosed |
| WO-2008002596-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PARP1 1520/4885ACHE 4227/4885ELANE 4267/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | PARP1 387/4885ACHE 3329/4885ELANE 232/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | PARP1 1520/4885ACHE 4227/4885ELANE 4267/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | PARP1 1163/4885ACHE 4127/4885ELANE 2366/4885 |
| US-20080255156-A1 | ADENOSINE A2A RECEPTOR ANTAGONISTS | ADORA3, ADORA2A, ADORA1 | PARP1 1571/4885ACHE 349/4885ELANE 3298/4885 |
| US-20240376117-A1 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | ALK, ACVR2B, ACVR2A | PARP1 3505/4885ACHE 4702/4885ELANE 4469/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | PARP1 1520/4885ACHE 4227/4885ELANE 4267/4885 |
| US-12054492-B2 | Imidazole-containing inhibitors of ALK2 kinase | ALK, ACVR2B, ACVR2A | PARP1 3505/4885ACHE 4702/4885ELANE 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.